Mural Oncology PLC
MURA2.040USD
0.000
Close 12/19, 16:00（ET）Quotes delayed by 15 min
35.34MMarket Cap
LossP/E TTM
More Details of Mural Oncology PLC Company
Mural Oncology plc is Ireland-based clinical-stage oncology company. The Company is a biotechnology company focused on using its protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer with the goal of delivering meaningful and clinical benefits to people living with cancer. The Company is developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers, particularly those with limited treatment options available. The lead product candidate, nemvaleukin alfa (nemvaleukin), is an investigational-engineered cytokine fusion protein that selectively binds to the intermediate-affinity interleukin-2 (IL-2) receptor. The Company has also developed engineered therapies targeting the interleukin-18 (IL-18) and interleukin-12 (IL-12) pathways, which have demonstrated therapeutic potential in third-party preclinical and clinical studies.
Mural Oncology PLC Info
Ticker SymbolMURA
Company nameMural Oncology PLC
IPO dateNov 03, 2023
CEOOwen Hughes (Owen)
Number of employees116
Security typeOrdinary Share
Fiscal year-endNov 03
Address10 Earlsfort Terrace
CityDUBLIN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIreland
Postal codeD02 T380
Phone35319058020
Websitehttps://www.muraloncology.com/
Ticker SymbolMURA
IPO dateNov 03, 2023
CEOOwen Hughes (Owen)
Company Executives of Mural Oncology PLC
Name
Name/Position
Position
Shareholding
Change
Ms. Maiken Keson-Brookes
Ms. Maiken Keson-Brookes
Chief Legal Officer
Chief Legal Officer
--
-100.00%
Mr. Owen Hughes
Mr. Owen Hughes
Chief Executive Officer, Secretary, Director
Chief Executive Officer, Secretary, Director
--
--
Mr. Bradley Sitko
Mr. Bradley Sitko
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Maiken Keson-Brookes
Ms. Maiken Keson-Brookes
Chief Legal Officer
Chief Legal Officer
--
-100.00%
Mr. Owen Hughes
Mr. Owen Hughes
Chief Executive Officer, Secretary, Director
Chief Executive Officer, Secretary, Director
--
--
Mr. Bradley Sitko
Mr. Bradley Sitko
Director
Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Fri, Dec 19
Updated: Fri, Dec 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Hudson View Capital LLC
4.41%
Oddo BHF Asset Management S.A.S
3.97%
OrbiMed Advisors, LLC
3.39%
Newtyn Management, LLC
3.01%
OMERS Administration Corporation
2.95%
Other
82.26%
Shareholders
Shareholders
Proportion
Hudson View Capital LLC
4.41%
Oddo BHF Asset Management S.A.S
3.97%
OrbiMed Advisors, LLC
3.39%
Newtyn Management, LLC
3.01%
OMERS Administration Corporation
2.95%
Other
82.26%
Shareholder Types
Shareholders
Proportion
Hedge Fund
12.65%
Corporation
11.21%
Investment Advisor
8.21%
Investment Advisor/Hedge Fund
7.80%
Private Equity
3.39%
Pension Fund
2.95%
Individual Investor
1.80%
Research Firm
1.67%
Venture Capital
0.06%
Other
50.26%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
284
9.82M
56.64%
-6.21M
2025Q2
284
12.51M
72.24%
-2.17M
2025Q1
276
9.96M
57.68%
-3.88M
2024Q4
267
10.64M
62.38%
-3.39M
2024Q3
261
11.92M
69.96%
-2.18M
2024Q2
251
12.21M
72.10%
-1.15M
2024Q1
240
12.61M
74.53%
-809.88K
2023Q4
223
13.72M
82.19%
+9.60M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Hudson View Capital LLC
765.60K
4.42%
+765.60K
--
Apr 16, 2025
OrbiMed Advisors, LLC
588.80K
3.4%
+588.80K
--
Jun 30, 2025
Newtyn Management, LLC
570.00K
3.29%
--
--
Jun 30, 2025
Samara Master Fund Ltd
494.12K
2.85%
+494.12K
--
Apr 21, 2025
Parkwood Master Fund Ltd
494.12K
2.85%
+494.12K
--
Apr 21, 2025
The Vanguard Group, Inc.
772.85K
4.46%
-11.22K
-1.43%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
283.12K
1.63%
-11.04K
-3.75%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.01%
Fidelity Small-Mid Multifactor ETF
0%
Vanguard ESG U.S. Stock ETF
0%
Avantis Responsible US Equity ETF
0%
Invesco RAFI US 1500 Small-Mid ETF
0%
Harbor Health Care ETF
0%
Fidelity MSCI Health Care Index ETF
0%
Global X Russell 2000 Covered Call ETF
0%
SPDR SSGA US Small Cap Low Volatility Index ETF
0%
Schwab 1000 Index ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.01%
Fidelity Small-Mid Multifactor ETF
Proportion0%
Vanguard ESG U.S. Stock ETF
Proportion0%
Avantis Responsible US Equity ETF
Proportion0%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0%
Harbor Health Care ETF
Proportion0%
Fidelity MSCI Health Care Index ETF
Proportion0%
Global X Russell 2000 Covered Call ETF
Proportion0%
SPDR SSGA US Small Cap Low Volatility Index ETF
Proportion0%
Schwab 1000 Index ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Mural Oncology PLC?
The top five shareholders of Mural Oncology PLC are:
Hudson View Capital LLC holds 765.60K shares, accounting for 4.42% of the total shares.
OrbiMed Advisors, LLC holds 588.80K shares, accounting for 3.40% of the total shares.
Newtyn Management, LLC holds 570.00K shares, accounting for 3.29% of the total shares.
Samara Master Fund Ltd holds 494.12K shares, accounting for 2.85% of the total shares.
Parkwood Master Fund Ltd holds 494.12K shares, accounting for 2.85% of the total shares.
Hudson View Capital LLC holds 765.60K shares, accounting for 4.42% of the total shares.
OrbiMed Advisors, LLC holds 588.80K shares, accounting for 3.40% of the total shares.
Newtyn Management, LLC holds 570.00K shares, accounting for 3.29% of the total shares.
Samara Master Fund Ltd holds 494.12K shares, accounting for 2.85% of the total shares.
Parkwood Master Fund Ltd holds 494.12K shares, accounting for 2.85% of the total shares.
What are the top three shareholder types of Mural Oncology PLC?
The top three shareholder types of Mural Oncology PLC are:
Hudson View Capital LLC
Oddo BHF Asset Management S.A.S
OrbiMed Advisors, LLC
Hudson View Capital LLC
Oddo BHF Asset Management S.A.S
OrbiMed Advisors, LLC
How many institutions hold shares of Mural Oncology PLC (MURA)?
As of 2025Q3, 284 institutions hold shares of Mural Oncology PLC, with a combined market value of approximately 9.82M, accounting for 56.64% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -15.60%.
What is the biggest source of revenue for Mural Oncology PLC?
In --, the -- business generated the highest revenue for Mural Oncology PLC, amounting to -- and accounting for --% of total revenue.
